[{"id":"9a2be334-2a03-47f4-bac6-d53ac52c474b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05286801","created_at":"2022-03-18T11:54:26.510Z","updated_at":"2025-02-25T14:08:43.679Z","phase":"Phase 1/2","brief_title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","source_id_and_acronym":"NCT05286801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA • SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["TNFA • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-19"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"a00222c5-3654-4b1c-8e1f-3f6063d2350d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03083678","created_at":"2021-01-18T15:11:26.156Z","updated_at":"2025-02-25T15:10:32.768Z","phase":"Phase 2","brief_title":"Afatinib in Locally Advanced and Metastatic Chordoma","source_id_and_acronym":"NCT03083678","lead_sponsor":"Leiden University Medical Center","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-13"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"b4088fdb-ec50-47ff-acf6-df6ef4b30a62","acronym":"TAZNI","url":"https://clinicaltrials.gov/study/NCT05407441","created_at":"2022-06-07T22:59:09.709Z","updated_at":"2025-02-25T14:17:01.156Z","phase":"Phase 1/2","brief_title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","source_id_and_acronym":"NCT05407441 - TAZNI","lead_sponsor":"Susan Chi, MD","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-09-13"},{"id":"4f28ce0c-9a5a-4a61-b5dd-312c3d0839fe","acronym":"KEYNOTE-A10","url":"https://clinicaltrials.gov/study/NCT03058289","created_at":"2021-01-18T15:03:51.688Z","updated_at":"2025-02-25T14:37:17.876Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","source_id_and_acronym":"NCT03058289 - KEYNOTE-A10","lead_sponsor":"Intensity Therapeutics, Inc.","biomarkers":" MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B","pipe":"","alterations":" ","tags":["MSI • CD8 • PD-1 • IFNG • IL6 • LAG3 • TNFA • CTLA4 • CD4 • IL2 • ICOS • IL10 • FOXP3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • cisplatin/vinblastine/SHAO-FA (INT230-6)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2024-08-13"},{"id":"a5409d19-a682-484b-8074-dbc0380cdead","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601950","created_at":"2021-01-17T17:38:36.460Z","updated_at":"2024-07-02T16:35:07.229Z","phase":"Phase 2","brief_title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02601950","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34 • SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["CD34 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 267","initiation":"Initiation: 12/22/2015","start_date":" 12/22/2015","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-29"},{"id":"8086c59c-d398-45e2-9f6f-5158e36590e7","acronym":"PalboSarc","url":"https://clinicaltrials.gov/study/NCT03242382","created_at":"2021-01-18T16:01:11.999Z","updated_at":"2024-07-02T16:35:22.689Z","phase":"Phase 2","brief_title":"Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.","source_id_and_acronym":"NCT03242382 - PalboSarc","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" CDKN2A • CDK4","pipe":" | ","alterations":" CDKN2A mutation • CDK4 overexpression","tags":["CDKN2A • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CDK4 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/31/2017","start_date":" 03/31/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-23"},{"id":"e58e210e-108e-41ab-9c0f-bb34d9683315","acronym":"","url":"https://clinicaltrials.gov/study/NCT04416568","created_at":"2021-01-18T21:17:09.710Z","updated_at":"2024-07-02T16:35:27.889Z","phase":"Phase 2","brief_title":"Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers","source_id_and_acronym":"NCT04416568","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 08/14/2020","start_date":" 08/14/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-28"},{"id":"1bcbbcb1-c23e-4cd4-863e-77a53309b4a2","acronym":"NCT-PMO-1601","url":"https://clinicaltrials.gov/study/NCT03110744","created_at":"2021-01-18T15:19:35.640Z","updated_at":"2024-07-02T16:35:52.226Z","phase":"Phase 2","brief_title":"CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma","source_id_and_acronym":"NCT03110744 - NCT-PMO-1601","lead_sponsor":"University Hospital Heidelberg","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B","pipe":"","alterations":" ","tags":["CDKN2A • RB1 • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-03-27"},{"id":"6759d127-572c-4154-9c23-d5091da77629","acronym":"","url":"https://clinicaltrials.gov/study/NCT05519917","created_at":"2022-08-29T13:03:16.217Z","updated_at":"2024-07-02T16:36:03.178Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma","source_id_and_acronym":"NCT05519917","lead_sponsor":"Huashan Hospital","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 expression • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2022-09-30"},{"id":"fa58d62b-eb7a-4259-85da-03ca35c7b9bd","acronym":"CHORDOMES","url":"https://clinicaltrials.gov/study/NCT04486820","created_at":"2021-01-18T21:32:20.614Z","updated_at":"2024-07-02T16:36:42.757Z","phase":"","brief_title":"Immunohistochemical Study of Chordomas to Improve Their Diagnosis and Prognosis Care","source_id_and_acronym":"NCT04486820 - CHORDOMES","lead_sponsor":"Centre Hospitalier Universitaire de Saint Etienne","biomarkers":" PD-L1 • CD8 • FOXA1 • CDX2 • INSM1","pipe":" | ","alterations":" PD-L1 expression • CDX-2 expression","tags":["PD-L1 • CD8 • FOXA1 • CDX2 • INSM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CDX-2 expression"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-07-27"},{"id":"ee2359d4-314f-402b-b016-07b5131d6e97","acronym":"","url":"https://clinicaltrials.gov/study/NCT00150072","created_at":"2021-01-18T23:14:50.146Z","updated_at":"2024-07-02T16:37:25.097Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Imatinib in Chordoma","source_id_and_acronym":"NCT00150072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PDGFRB • PDGFB","pipe":"","alterations":" ","tags":["PDGFRB • PDGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 04/01/2008","study_completion_date":" 04/01/2008","last_update_posted":"2017-02-23"}]